Eluvia™ Drug-Eluting Stent

Eluvia is the standard in real-world evidence

Same patients, different device, proven outcomes

Across meta-analyses, head-to-head RCTs and real-world studies, Eluvia's outcomes hold up study after study. As new data is released, you'll find it here: another study, another reason Eluvia is THE STANDARD.

Check out more real-world evidence at...
TCT | VEITH | PVI

ELEGANCE Registry 12 Month Data Set¹

Released Oct 6^th, 2026

ELEGANCE Registry. Patients treated with Eluvia showed consistently positive 12-month outcomes.

ELEGANCE Registry. 12-month freedom from CD-TLR.

ELEGANCE Registry. 12-month freedom from major amputation.

ELEGANCE Registry. Post Market Regsitry: Non-randomized, prospective, global, multi-center. Diverse enrollment objective: greater than 40% women, greater than 40% URM. Treatment target: lesions in peripheral arterial circulation. Evaluation & follow-up: per site and treating physician standard of care.

ELEGANCE Registry Page 1
ELEGANCE Registry Page 2
ELEGANCE Registry Page 3
ELEGANCE Registry Page 4

Download the ELEGANCE 12-month sheet

TRUE-PTX Eluvia Subgroup Analysis²

Before matching

12-month amputations occurred less frequently for patients treated with Eluvia DES

	Eluvia	non-DE	P-value
Any Limb Amputation	7.7%	8.9%	0.265
Same Limb Amputation	1.9%	2.3%	0.391
Any Readmission	51.9%	57.8%	0.001

After Matching³

Patients treated with non-DE devices were more likely to have any above-ankle amputation and any readmission compared with Eluvia DES

Treatment with a non-DE device increased odds for any above-ankle amputation by

47%

Treatment with a non-DE device increased odds for any readmission by

23%

Learn more about the standard

Drug Elution case library

See how physicians are using drug-eluting technologies in real-world practice.

View case studies

Contact us

Connect with an Eluvia representative to learn more about the standard for SFA stenting.

Reach out today

Full drug elution portfolio

Explore our comprehensive range of drug-eluting technologies designed to improve patient outcomes.

Explore more

Eluvia indications, safety, and warnings

References:

1. Secemsky E, on behalf of the ELEGANCE Investigators. 12-month Outcomes for Patients with Complex PAD Treated with Eluvia DES from the ELEGANCE Registry. VIVA 2026 Scientific Sessions, Las Vegas, NV; 2026.
2. Brian DeRubertis. Polymer-based Drug-Eluting Stent vs Bare Device Therapies for PAD In the Real World: 12-Month Amputation and Readmission Rates in a Large Nationwide Population. Presented at CX 23 April 2025.
3. Exact Matching Method.

My account